Volume boom masks 56% PAT cliff; new units ramp, execution risks linger

Revenue +36% but consolidated PAT fell 56% YoY to ₹37 Cr; EBITDA +20% on margin compression

Kondapur had 10 days in Q1 (first patient June 20), July did ₹45 Cr; Mahadevapura Q1 EBITDA loss ₹15 Mn but June month profitable, July ₹20 Cr revenue

Thane EBITDA losses flat 3 quarters (Q2/Q3/Q4 FY26), July improvement to ₹21 Cr (10% margin) requires sustained trajectory; old Kondapur drag ₹15-16 Cr annually for 6+ months

QIP ₹1,500 Cr raised (June 24), ₹1,125 Cr repaid by July 1, debt ₹3,250 Cr → ₹2,400 Cr; financial engineering real, but CAPEX intensive growth model continues

IP ₹72,493 units (+26.6% YoY), OP 6,58,617 units (+28.5% YoY); volume growth genuine, but occupancy still 50-52% in mature Telangana (61% ex non-functional beds)

Prior: Thane/Electronic City Q2/Q3 breakeven. Actual: Thane 3-quarter flat losses, Electronic City still in red Q1. Requires sequential monthly ramp (July: Thane ₹21 Cr, 10% margin) to hit FY27 neutrality.

Prior qualitative: continued growth. Actual Q1 FY27: ₹37 Cr vs ₹85 Cr prior year (-56%). Management offered no explicit PAT growth target for FY27; deferred margin trajectory note.

QIP ₹1,500 Cr vs prior target ₹1,300 Cr, ₹1,125 Cr deployed Q1 vs prior aspiration to reduce debt-to-EBITDA 1:2 by year-end.

Prior (implied): baseline unit ₹350+ Cr EBITDA. New: ₹1,200 Cr revenue potential (₹100 Cr/month at scale, 4-5 years). New clinical programs (oncology, transplant) added as tailwind.

Prior: path to 65-70% occupancy. Actual: Telangana 50-52% (61% ex non-functional/Kondapur beds), no improvement Q4→Q1 despite new units. Analyst pressed, management deferential.

Focus on Kondapur (just commissioned), Thrissur (3-4 months away), neutralize EBITDA in prior-year units. Risks mitigated by QIP debt repayment and positive govt receivables trend.

Kerala in growth phase, single-digit EBITDA margins, mid-teens by FY28, 20-22% by FY30. ARPOB reflects ALOS reduction, not case mix; ARPP is better metric. Demand strong across clusters.

Pause on greenfield, focus on stabilizing current hospitals next 3 quarters. Resume greenfield/acquisition after. Core markets (Telangana, Andhra, Karnataka, Kerala, Maharashtra) have room for both.

Very marginal Q1 losses (₹2 Cr/month pre-ops June). July ramp strong (₹45 Cr revenue, losses minimal). Old facility still operational 6 months, rental drag ₹0.9 Cr/month.

Will settle to ₹80-85K post-empanelment ramp. Currently quaternary-care mix (complex cases, lower ALOS), inflating ARPOB. Strategic positioning, not structural.

Maharashtra culture: doctors prefer part-time, convert slowly to full-time. Empanelment delays (May GIPSA, June tumor). July ₹21 Cr (10% margin), trajectory shifting. Nagpur precedent: 18-24 months to stabilize then robust growth (₹30 Cr July revenue).

At 61% occupancy ex non-functional beds + Kondapur. By FY30, 65-70% doable with no new bed additions; 30% EBITDA margin achievable.

Golden Lan (Telangana, 300 beds near Kondapur): ₹90-95 Cr monthly revenue potential. Sarvottam (Kakinada, ₹7-8 Cr current) → ₹15-20 Cr potential. O&M agreement, losses don't hit P&L. Acquisition after ramp-up. Rajahmundry greenfield ₹60-75 Cr CAPEX FY27.

Minority interest 10-15% range. Maintenance CAPEX ₹100 Cr/year; next 3-4 years ₹2,500+ Cr OCF after ₹400-500 Cr CAPEX. Deploy excess for greenfield/brownfield, maintain 2.5:1 leverage.

Prior ₹26 FY showed 31% Telangana margin. Mature units (Secunderabad, old Kondapur) at 34-35%. New bed capacity drag 2-3 years. Kerala entry cost 4-5%, so 22% settled vs blended.

₹90 Lakh/month rent + ₹3-4 Cr opex annually. Decision in 6 months. ~₹12 Cr annual rental + ₹3-4 Cr opex drag until closure.

Model 30% conservatively; 35-40% requires clinical program maturity 3+ years. New oncology, transplant, other programs need ramp time. Don't assume immediate 35%+ at scale.

50% empanelled for 4 assets (Thane, Nashik, 2x Bangalore). Remaining 50% with definitive timelines now. Big ones done by mid-Sep FY27.

4-5% is fair, not aggressive. Inflationary baseline ~6-7% but case-mix normalizes from current quaternary-heavy state. Conservative is prudent.

MD: 'aiming for year-on-year growth historically...last 10, 15 years.' Q1 delivered 35%; likely moderates to high-20s by year-end due to new-unit mix. No full-year target provided.

Qualitative, phased. Telangana drag from new bed capacity 2-3 years. Management deferred H2/FY28 margin trajectory to post-call note; non-committal on consolidated NPM recovery timeline.

Analyst questioned if 4-5% too conservative vs historical 15-16%. Management said 4-5% appropriate given quaternary-to-blended case-mix evolution. Conservative positioning.

CAPEX % of sales not quantified. Management promised disclosure post-call. Greenfield 70%, acquisition/O&M 0% (O&M pays no losses). Suggests moderate CAPEX run vs prior expansion phase.

Thane, Electronic City, Kerala, new Bangalore units still 6-12 months from profitability. Empanelment only 50% done for 4 assets; delays directly compress Q2/Q3 ramp and push breakeven into FY28.

Telangana occupancy flat Q4→Q1 despite strong IP/OP volume growth (26.6%/28.5% YoY). Bed capacity up 450 (Kondapur), but occupied beds not moved. Analyst pressed on gap; management deflected to 'non-functional bed adjustment' (Secunderabad 250 beds under renovation/demolition).

Q1 FY27 consolidated PAT ₹37.4 Cr vs ₹85 Cr (Q1 FY26), down 56% YoY despite 35% revenue growth. EBITDA grew only 14.6%. Minority interest (10.5%), consolidated pre-Ind AS adjustments, finance costs, and new-unit losses (₹20-30 Cr estimated) eroding profit. Old Kondapur facility ₹15-16 Cr drag for 6+ months.

Bangalore hospitals reporting ₹90K+ ARPOB vs ₹70-75K initial guidance. Management concedes empanelment ramp will normalize mix, targeting ₹80-85K post-corporate empanelment. ARPP (better metric) grew only 6.8% YoY, suggesting underlying case-mix shift to lower acuity (higher ALOS reduction offset ARPOB gains).

After ₹1,125 Cr debt repay via QIP, management commits to maintain 2.5:1 debt-to-equity and deploy excess FCF for greenfield/brownfield. CAPEX ₹100-125 Cr annualized, maintenance ₹100 Cr/yr, implies ₹2,000+ Cr cumulative 3-4 yr deployment. Growth model remains CAPEX-driven, not free-cash-flow positive.

Thane, Nashik, Nagpur ramp slower than Telangana/Andhra peers. Doctors prefer part-time practice, resist exclusive KIMS commitment. Nagpur took 18-24 months before stabilization; now ₹30 Cr July revenue. Thane still in losses 3Q straight; May/June empanelment delays compounded.